Bioventus (BVS) Cost of Revenue (2020 - 2026)

Bioventus (BVS) has reported Cost of Revenue for 7 consecutive years, with $47.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 4.33% year-over-year to $47.5 million; the trailing twelve-month figure through Jun 2026 stood at $182.4 million (changed 0.21% YoY), and the FY2025 full-year result was $179.9 million, down 2.77% from the prior year.
• Cost of Revenue rose to $47.5 million in Q2 2026 per BVS's latest filing, from $41.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $51.6 million in Q4 2022 and bottomed at $40.8 million in Q1 2025.
• Historically, Cost of Revenue has averaged $45.5 million across 5 years, with a median of $45.3 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue surged 87.15% in 2022, then retreated 9.0% in 2024.
• Over 5 years, Cost of Revenue stood at $51.6 million in 2022, then decreased by 4.89% to $49.1 million in 2023, then grew by 3.79% to $51.0 million in 2024, then fell by 3.66% to $49.1 million in 2025, then slipped by 3.21% to $47.5 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $47.5 million, $41.3 million, and $49.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.